Company intelligence / Profile preview

PreDiCTR

Cambridge, Cambridgeshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

PreDiCTR is a biotechnology company focused on transforming cancer treatment through a proprietary functional genomics platform that identifies optimal drug targets within the DNA damage response (DDR) pathway. By utilizing high-throughput screening and advanced bioinformatics, the company aims to develop precision medicines that exploit specific genetic vulnerabilities in tumors. Their approach focuses on overcoming resistance to current therapies and improving patient outcomes in hard-to-treat cancers. PreDiCTR's lead programs are currently in the pre-clinical stage, targeting novel nodes in the DDR network to create next-generation oncology therapeutics.

Therapeutic areas: Oncology
Modalities: Small moleculeDrug discovery platform
Industry: Biotech

Beyond the preview

Go deeper on PreDiCTR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PreDiCTR.

Explore the full profile